The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

Hims & Hers Health Inc. investors have sued the telehealth provider days after Novo Nordisk A/S announced it was ending the ...

Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss ...

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Novo Nordisk has bounced back from a sour ending to its Hims & Hers partnership, revealing a new deal with WeightWatchers to ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Novo Nordisk (NVO) has partnered with WeightWatchers (OTC:WGHTQ) to sell its obesity drug Wegovy days after exiting a similar ...

Novo Nordisk plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

She began using Wegovy, the version of Ozempic approved for weight loss, after struggling with obesity. She reveals which foods to avoid on a GLP-1 and how to prevent muscle loss.

No matter how much you love these speculative winners, you don’t have a gain until you actually ring the register.